26 January 2021 EMA/CHMP/47240/2021 Corr.11 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 25-29 January 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 25 January 2021, 09:00 – 19:30, virtual meeting/ room 1C 26 January 2021, 08:30 – 19:30, virtual meeting/ room 1C 27 January 2021, 08:30 – 19:30, virtual meeting/ room 1C 28 January 2021, 08:30 – 19:30, virtual meeting/ room 1C 29 January 2021, 08:30 – 18:00, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Correction in section 9.1.5 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Introduction 8 1.1. Welcome and declarations of interest of members, alternates and experts ............ 8 1.2. Adoption of agenda ................................................................................................ 8 1.3. Adoption of the minutes ......................................................................................... 8 2. Oral Explanations 8 2.1. Pre-authorisation procedure oral explanations ....................................................... 8 2.1.1. salmeterol xinafoate / fluticasone propionate - EMEA/H/C/005591 ................................... 8 2.1.2. salmeterol xinafoate / fluticasone propionate - EMEA/H/C/004881 ................................... 8 2.1.3. COVID-19 Vaccine (ChAdOx1-S [recombinant]) – EMEA/H/C/005675 ............................... 9 2.2. Re-examination procedure oral explanations ......................................................... 9 2.3. Post-authorisation procedure oral explanations ..................................................... 9 2.3.1. Epidyolex - cannabidiol - Orphan - EMEA/H/C/004675/II/0005 ........................................ 9 2.3.2. Trelegy Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004363/X/0012/G ............................................................................................................................... 9 2.4. Referral procedure oral explanations ................................................................... 10 3. Initial applications 10 3.1. Initial applications; Opinions ................................................................................ 10 3.1.1. bevacizumab - EMEA/H/C/005286 ............................................................................. 10 3.1.2. salmeterol xinafoate / fluticasone propionate - EMEA/H/C/005591 ................................. 10 3.1.3. remimazolam - EMEA/H/C/005246 ............................................................................. 10 3.1.4. dostarlimab - EMEA/H/C/005204 ............................................................................... 11 3.1.5. ofatumumab - EMEA/H/C/005410 .............................................................................. 11 3.1.6. selinexor - Orphan - EMEA/H/C/005127 ..................................................................... 11 3.1.7. cenobamate - EMEA/H/C/005377 .............................................................................. 11 3.1.8. bevacizumab - EMEA/H/C/005556 ............................................................................. 11 3.1.9. pemigatinib - Orphan - EMEA/H/C/005266 .................................................................. 12 3.1.10. salmeterol xinafoate / fluticasone propionate - EMEA/H/C/004881 ................................. 12 3.1.11. somapacitan - Orphan - EMEA/H/C/005030 ................................................................ 12 3.1.12. thiotepa - EMEA/H/C/005434 .................................................................................... 12 3.1.13. icosapent ethyl - EMEA/H/C/005398 .......................................................................... 13 3.1.14. COVID-19 Vaccine (ChAdOx1-S [recombinant]) – EMEA/H/C/005675 ............................. 13 3.1.15. Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735 ........... 13 3.1.16. COVID-19 Vaccine Moderna – COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791 ................................................................................................... 13 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) ...................................................................... 14 Committee for medicinal products for human use (CHMP) EMA/CHMP/47240/2021 Page 2/41 3.2.1. abiraterone acetate - EMEA/H/C/005408 .................................................................... 14 3.2.2. hydrocortisone - Orphan - EMEA/H/C/005105 ............................................................. 14 3.2.3. estetrol / drospirenone - EMEA/H/C/005336................................................................ 14 3.2.4. risdiplam - Orphan - EMEA/H/C/005145 ..................................................................... 14 3.2.5. pralsetinib - EMEA/H/C/005413 ................................................................................. 14 3.2.6. estetrol / drospirenone - EMEA/H/C/005382................................................................ 15 3.2.7. ponesimod - EMEA/H/C/005163 ................................................................................ 15 3.2.8. tanezumab - EMEA/H/C/005189 ................................................................................ 15 3.2.9. relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267 .................................. 15 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) ...................................................................... 15 3.3.1. abrocitinib - EMEA/H/C/005452 ................................................................................. 15 3.3.2. artesunate - Orphan - EMEA/H/C/005550 ................................................................... 16 3.3.3. avalglucosidase alfa - Orphan - EMEA/H/C/005501 ...................................................... 16 3.3.4. ranibizumab - EMEA/H/C/005545 .............................................................................. 16 3.3.5. lonapegsomatropin - Orphan - EMEA/H/C/005367 ....................................................... 16 3.3.6. adalimumab - EMEA/H/C/005548 .............................................................................. 16 3.3.7. teriparatide - EMEA/H/C/004932 ............................................................................... 16 3.3.8. pegcetacoplan - Orphan - EMEA/H/C/005553 .............................................................. 16 3.3.9. ripretinib - Orphan - EMEA/H/C/005614 ..................................................................... 17 3.3.10. rivaroxaban - EMEA/H/C/005600 ............................................................................... 17 3.3.11. autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated - Orphan - ATMP - EMEA/H/C/003693 .......................................................................... 17 3.3.12. elivaldogene autotemcel - Orphan - ATMP - EMEA/H/C/003690 ..................................... 17 3.4. Update on on-going initial applications for Centralised procedure ........................ 17 3.4.1. zanubrutinib - Orphan - EMEA/H/C/004978 ................................................................. 17 3.4.2. leuprorelin - EMEA/H/C/005034 ................................................................................. 18 3.4.3. doxorubicin hydrochloride - EMEA/H/C/005330 ........................................................... 18 3.4.4. doxorubicin - EMEA/H/C/005320 ............................................................................... 18 3.4.5. sildenafil - EMEA/H/C/005439 ................................................................................... 18 3.4.6. sitagliptin - EMEA/H/C/005598 .................................................................................. 19 3.4.7. trastuzumab - EMEA/H/C/005066 .............................................................................